Abstract
A major European randomised study of screening for prostate cancer has been launched. Pilot studies have already been conducted in several centres, and working groups in Belgium, Italy and the Netherlands are confirmed participants. Working parties in Finland, Portugal and the United Kingdom are candidate participants.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bentvelsen FM, Schröder FH (1993) Modalities available for screening for prostate cancer. Eur J Cancer 29A(6):804–811
Boyle P, Alexander FE (1994) Screening for prostate cancer: principles, design and evaluation, European Institute of Oncology Technical Report 94/005. European Institute of Oncology, Milan, Italy
Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161
Colberg JW, Smith DS, Catalona WJ (1993) Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0ng/ml. J Urol 149:507–509
de Koning HJ (1993) Grant appliction to the Dutch Cancer Society and Prevention Fund
Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumour extent of non-palpable (stage Tlc) prostate cancer. JAMA 2715:368–374
Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J-L, Emond J (1992) Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147:846–852
Mettlin C, Lee F, Drago J, Murphy GP, Investigators of the American Cancer Society National Prostate Cancer Detection Project (1991) The American Cancer Society National Prostate Cancer Detection Project. Cancer 67:2949–2958
Oesterling JE, Jacobsen SJ, Chute CG et al (1993) Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864
Oesterling JE, Martin SK, Bergstrahl EJ, Lowe FC (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269(l):57–60
Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT (1994) The pathological features and prognosis of prostate cancers detectable with current tests. J Urol (in press)
Prorok PC (1991) PLCO study proposal. Biometry and Early Detection Branches, National Cancer Institute, USA
Schröder FH (1993) Prostate cancer: to screen or not to screen? Br Med J 306:407
Schröder FH, Boyle P (1963) Screening for prostate cancer — necessity or nonsense? Eur J Cancer 29:656
Schröder FH, Denis L, Kirkels WJ, de Koning HJ, Standaert B (1994) European randomised study of screening for prostate cancer. Cancer (in press)
Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localised prostate cancer. Relationship of tumour volume to clinical significance for treatment of prostate cancer. Cancer 71:933–938
Wilson JMG, Jungner G (1968) Principles and practice of screening for disease Public Health Paper no 34. WHO, Geneva
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schröder, F.H. (1995). Screening for Prostate Cancer: Practical Aspects. In: Garraway, M. (eds) Epidemiology of Prostate Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78826-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-78826-0_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78828-4
Online ISBN: 978-3-642-78826-0
eBook Packages: Springer Book Archive